N,N-二甲基-3-(8-硝基-5,6-二氢苯并[b][1]苯并氮杂卓-11-基)丙-1-胺 | 77533-92-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 中文名称: N,N-二甲基-3-(8-硝基-5,6-二氢苯并[b][1]苯并氮杂卓-11-基)丙-1-胺
• 英文名称: 2-nitro-5-(3'-dimethylaminopropyl)-10,11-dihydro-5H-dibenzazepine
• 英文别名: 2-Nitroimipramine；N,N-dimethyl-3-(3-nitro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)propan-1-amine
• CAS: 77533-92-7
• 化学式: C₁₉H₂₃N₃O₂
• 分子量: 325.411
• InChiKey: JYLKYRDTRZHXAJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  52.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  5-nitroso-10,11-dihydro-5H-dibenzazepine 在 盐酸 、 过氧化氢苯甲酰 、 sodium hydride 作用下， 以 甲醇 、 氯仿 为溶剂， 反应 32.5h， 生成 N,N-二甲基-3-(8-硝基-5,6-二氢苯并[b][1]苯并氮杂卓-11-基)丙-1-胺
  参考文献：
  名称：

  Horowska, Barbara; Ledochowski, Andrzej, Polish Journal of Chemistry, 1981, vol. 55, # 1, p. 39 - 46

  摘要：

  DOI：

文献信息

• Reagents and methods for the quantification of amitriptyline or
  申请人：Abbott Laboratories

  公开号：US05407835A1

  公开（公告）日：1995-04-18

  Immunoassay methods and reagents for the specific quantification of amitriptyline or nortriptyline in a test sample are disclosed employing antibodies prepared with amitriptyline or nortriptyline derivatives of the Formula III: ##STR1## wherein for amitriptyline, R is CH.sub.3, and for nortriptyline, R is H. The present invention also describes the synthesis of unique fluorescein tracers of the structure of Formula IV and Formula V: ##STR2## wherein for a specific amitriptyline immunoassay, W.sub.1 is a heteroatom linked to the aromatic ring at the 2 or 3 position, and for a specific nortriptyline immunoassay, W.sub.2 is two heteroatoms linked together and attached to the aromatic ring at the 2 or 3 position, and wherein Q is a detectable moiety, preferably fluorescein or a fluorescein derivative.

  本发明涉及一种用于特定定量测定检测样品中阿米替林或诺替林的免疫测定方法和试剂，采用用阿米替林或诺替林衍生物制备的抗体，该衍生物的化学式为III式：##STR1##其中对于阿米替林，R为CH.sub.3，对于诺替林，R为H。本发明还描述了结构式IV和V的独特荧光素示踪剂的合成：##STR2##其中对于特定的阿米替林免疫测定，W.sub.1是连接到芳香环的2或3位置的杂原子，对于特定的诺替林免疫测定，W.sub.2是连接在一起并附着到芳香环的2或3位置的两个杂原子，其中Q是可检测的基团，优选为荧光素或荧光素衍生物。
• Reagents and methods for the quantification of imipramine or desipramine
  申请人：Abbott Laboratories

  公开号：US05340750A1

  公开（公告）日：1994-08-23

  Immunoassay methods and reagents for the specific quantification of imipramine or desipramine in a test sample are disclosed. The measurement of imipramine or desipramine is accomplished in a specific immunoassay employing antibodies prepared with imipramine or desipramine derivatives of the Formula III: ##STR1## wherein P is an immunogenic carrier material, X is two heteroatoms, Y is a linking group comprising from 1 to 6 carbon atoms and P is an immunogenic carrier material, and wherein for imipramine, R is CH.sub.3, and for desipramine, R is H. The present invention also describes the synthesis of unique labeled reagents of the structure of the Formula IV: ##STR2## wherein Z is a linking group comprising 1 to 4 carbon atoms and 0 to 2 heteroatoms and Q is a detectable moiety, preferably fluorescein or a fluorescein derivative, and wherein for imipramine, R.sub.1 is CH.sub.3, and for desipramine, R.sub.1 is H.

  本发明公开了一种用于特定定量检测测试样品中丙咪嗪或去甲丙咪嗪的免疫测定方法和试剂。通过使用用丙咪嗪或去甲丙咪嗪衍生物制备的抗体进行特定免疫测定，可以测量丙咪嗪或去甲丙咪嗪。其中衍生物的结构式为III：##STR1## 其中P为免疫原性载体材料，X为两个杂原子，Y为含有1到6个碳原子的连接基，P为免疫原性载体材料，对于丙咪嗪，R为CH.sub.3，对于去甲丙咪嗪，R为H。本发明还描述了结构式IV的独特标记试剂的合成：##STR2## 其中Z为含有1到4个碳原子和0到2个杂原子的连接基，Q为可检测的基团，优选为荧光素或荧光素衍生物，对于丙咪嗪，R.sub.1为CH.sub.3，对于去甲丙咪嗪，R.sub.1为H。
• SLOW-RELEASE FORMULATIONS OF 5-HYDROXYTRYPTOPHAN AS AN ADJUNCT TO PRO-SEROTONERGIC THERAPIES
  申请人：Duke University

  公开号：EP2629615B1

  公开（公告）日：2018-10-10
• Method for augmenting the effects of serotonin reuptake inhibitors
  申请人：Krishnan R. Ranga

  公开号：US20060142375A1

  公开（公告）日：2006-06-29

  A method of treating a subject for a serotonergic neurotransmission dysregulation disorder, comprises administering the subject a serotonin enhancer (e.g., a serotonin reuptake inhibitor) in an amount effective to treat the disorder; and concurrently administering the subject 5-hydroxytryptophan in an amount effective to enhance the activity of the serotonin enahancer, (e.g., serotonin reuptake inhibitor). In preferred embodiments the disorder is depression, anxiety, or substance abuse.
• METHOD FOR AUGMENTING THE EFFECTS OF SEROTONIN REUPTAKE INHIBITORS
  申请人：Krishnan Ranga R.

  公开号：US20090192166A1

  公开（公告）日：2009-07-30

  A method of treating a subject for a serotonergic neurotransmission dysregulation disorder, comprises administering the subject a serotonin enhancer (e.g., a serotonin reuptake inhibitor) in an amount effective to treat the disorder; and concurrently administering the subject 5-hydroxytryptophan in an amount effective to enhance the activity of the serotonin enhancer, (e.g., serotonin reuptake inhibitor). In preferred embodiments the disorder is depression, anxiety, or substance abuse.